Clinical Course and Outcomes of COVID-19 Infection in Patients Treated with Rituximab: A Tertiary Care Center Experience
Thamer S Alhowaish,Moustafa S Alhamadh,Alaa Mathkour,Marwan Alamoudi,Hossam Ali Alqahtani,Abdulrahman Alrashid
DOI: https://doi.org/10.2147/OARRR.S424316
2023-08-28
Open Access Rheumatology: Research and Reviews
Abstract:Thamer S Alhowaish, 1, 2 Moustafa S Alhamadh, 2, 3 Alaa Mathkour, 4 Marwan Alamoudi, 2, 5 Hossam Ali Alqahtani, 1, 2 Abdulrahman Alrashid 2, 3, 5 1 Division of Neurology, King Abdulaziz Medical City, Ministry of the National Guard Health Affairs, Riyadh, Kingdom of Saudi Arabia; 2 King Abdullah International Medical Research Center, Ministry of the National Guard Health Affairs, Riyadh, 11481, Kingdom of Saudi Arabia; 3 College of Medicine, King Saud Bin Abdulaziz University for Health Sciences (KSAUHS), Ministry of the National Guard-Health Affairs, Riyadh, 14611, Kingdom of Saudi Arabia; 4 Ministry of Health, Riyadh, 12613, Kingdom of Saudi Arabia; 5 Department of Medicine, Division of Rheumatology, King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Riyadh, Kingdom of Saudi Arabia Correspondence: Thamer S Alhowaish, Division of Neurology, Department of Medicine, King Abdulaziz Medical City, Ministry of the National Guard Health Affairs, P.O. Box 22490, Riyadh, 11426, Kingdom of Saudi Arabia, Email Introduction: Patients receiving rituximab (RTX) may be at increased risk for severe Coronavirus infections and worse outcomes compared with the general population. Because of the conflicting results concerning the effect of RTX on the clinical course and outcomes of COVID-19 infection, we aimed to share our experience with 35 patients infected with COVID-19 while treated with RTX for a variety of clinical indications. Methods: This was a single-centre retrospective cohort study that included 35 patients. All patients aged ≥ 14 years who were treated with RTX for various conditions and were found to have COVID-19 infection were included. Patients with poor outcomes or patients with suspected COVID-19 infection were excluded. Results: The patients' mean age was 42.8 ± 16.3 years with an average BMI of 29.9 ± 11.4 kg/m 2 . Over half (51.4%, n = 18) of the patients received RTX at a dose of 375 mg/m2 with a median frequency of 4 doses. More than a third (37.1%, n = 13) of the patients had hypogammaglobulinemia and 25.7% had low CD19. Over a third (42.9%, n= 15) of the patients required hospitalization and almost a third (25.7%, n = 9) required treatment in the intensive care unit. There was a statistically significant association between intensive care unit admission and age, steroid use, and low CD19. The mortality rate was 25.7%, and it was significantly higher in elderly, diabetics, corticosteroid users, patients who were hospitalized, treated in the intensive care unit, and had low immunoglobin or CD19. Conclusion: Treatment with RTX seems to be a potential risk factor for unfavorable outcomes in COVID-19 patients. RTX should be used with caution or avoided unless the benefit clearly outweighs the risk. Keywords: rituximab, SARS-CoV-2, COVID-19, autoimmunity, hypogammaglobulinemia, rheumatology Coronavirus is an enveloped, single-stranded RNA virus. Infection with this virus was first reported in Wuhan, China, in December 2019, and it was declared a pandemic in March 2020. Coronavirus disease 2019 (COVID-19) may present as mild to moderate, self-limiting respiratory symptoms such as fever, loss of taste and smell, cough, and shortness of breath, but in some patients, it may be severe enough to require hospitalization and intubation with mechanical ventilation. 1 Rituximab (RTX) is a monoclonal antibody that is used for the treatment of numerous diseases, including rheumatologic, hematologic, nephrologic, neurologic, and oncologic conditions. 2 RTX targets the B-cell transmembrane protein CD20, leading to B-cell destruction. As a result, RTX suppresses the humoral immunity via B-cell depletion. Although generally well-tolerated with only mild adverse effects such as infusion reactions, headache, and chills, RTX can induce severe immunosuppression, resulting in hypogammaglobulinemia, neutropenia, and reactivation of viral infections. 3 There is no consensus on whether immunosuppressive and immunomodulatory agents negatively affect the clinical course and outcome of COVID-19 infection. 4 To emphasize, some studies found that patients who were already taking immunosuppressive agents are more susceptible to COVID-19 infection and worse outcomes. 1,5 More specifically, multiple studies suggested that patients treated with RTX are at increased risk for severe COVID-19 infection and worse outcomes compared to the general population. Also, several reports revealed higher rates of COVID-19-related hospitalization, respiratory failure requiring intubation and mechanical ventilation, and -Abstract Truncated-